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SHC PROTEINS MEDIATE SIGNALING between cell surface receptors and the MAP kinase cascade. Shc proteins are expressed as three isoforms of 46, 52, and 66 kDa (p46 Shc , p52  Shc , and  p66 Shc , respectively), differing only in the length of the amino terminal domain (26) . All three isoforms are conserved across vertebrate classes and are alternative transcription and translation products of the same gene. Shc proteins are canonical substrates of receptor tyrosine kinases such as epidermal growth factor (EGF) receptors, but are also activated by TGF-␤ receptors (14) , integrins, hormone receptors, and G proteincoupled receptors (29) . Shc isoforms contain no identifiable enzymatic domains and function as adaptor proteins.
Upon tyrosine phosphorylation, the prototype p52
Shc isoform associates with two Grb2 adapter proteins and a SOS guanylnucleotide-exchange protein (31) . The resulting heterotrimer translocates to the plasma membrane where Ras GTPase is encountered and activated. Subsequently Raf, MEK, and the Erk MAP kinases are activated, ultimately resulting in mitogenic activation. Although incompletely characterized, the p46 Shc isoform appears to function by a similar mechanism (22) .
In contrast, the p66 Shc isoform has an antimitogenic function (22) . The p66
Shc is identical to p52 Shc except for a 109-amino acid CH2 domain appended to the NH 2 -terminus. Because p66
Shc and p52 Shc are phosphorylated by the same kinases and bind to the same downstream intermediates, it is postulated that p66 Shc antagonizes Ras activation by sequestering Grb2 (22, 25) . However, p66
Shc appears to confer additional signaling functions, including a unique oxidative stress signaling function that is dependent on CH2 serine phosphorylation (19) .
Unlike the ubiquitous p52 Shc isoform, p66 Shc is developmentally regulated. We have reported maturational regulation of p66
Shc in mouse, baboon, and human lungs (15, 16) . In the developing mouse lung, p66
Shc is ubiquitously expressed early in gestation, but becomes progressively restricted to bronchial airway epithelial cells with maturation. A dramatic decrease in p66
Shc expression occurs just before delivery on the 18th day of gestation, during the saccular stage of lung development. In baboons and humans, p66 Shc downregulation occurs during the canalicular stage, suggesting that its downregulation is necessary for pulmonary maturation. Conversely, p66 Shc is upregulated with induction of bronchopulmonary dysplasia in both humans and baboons, suggesting a promaturational function.
Because pulmonary p66 Shc is developmentally regulated across mammalian orders and mediates oxidative stress responses, it seems likely that p66
Shc regulates pulmonary morphogenesis in a time-and position-sensitive manner. However, mice bearing a constitutive p66
Shc deletion have no overt lung phenotype; indeed, these mice are resistant to oxidative stress and have longer lifespans (20) . Constitutive protein deletion selects for embryos that possess compensatory mechanisms, and a more realistic appraisal of p66
Shc function might be obtained from its conditional deletion. Unfortunately, p66
Shc differs from p52
Shc by a single splice reaction that excises the p52 Shc promoter, transcriptional start site, and part of the first exon (22) . Consequently, a 3= LoxP site that would enable inducible p66 Shc deletion will alter or terminate p52 Shc in its phosphotyrosine binding domain.
To assess its function in lung development, we attenuated p66
Shc expression using isoform-specific small-interfering RNA (siRNA) constructs. These constructs were transfected D E F A B C Fig. 1 . Transfection of the epithelial compartment of embryonic day 11 (E11) lungs does not alter morphogenesis in vitro. Cy5-conjugated nonsilencing small-interfering RNA (siRNA) was suspended in transfection reagent at 6.6 nM and microinjected in the tracheae of E11 lung explants until filled. Typically, 1 l of solution was instilled. After 3 days, lungs were visualized by epifluorescence and brightfield microscopy. A: no fluorescence is seen in uninjected lungs. B: selective uptake by epithelial cells was readily demonstrated after tracheal injection of labeled siRNA. C: expression of siRNA localization was also assessed in explants immersed in transfection mixtures. These also showed primarily epithelial uptake. The morphology of the same untransfected, tracheally injected, and immersed explants was similar (D, E, and F, respectively).
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Fig. 2. Tracheal p66
Shc siRNA reduces epithelial p66 Shc expression. The expression of p66 Shc was attenuated using an isoform-specific siRNA developed by Kisielow et al. (10) . The tracheae of E11 lungs were either not injected (A) or filled with transfection mixtures containing 6.6 nM nonsilencing siRNA (B), GAPDH siRNA (C), or p66
Shc siRNA (D). Lung explants were cultured for 3 days before fixation and immunostaining for p66 Shc , which localizes to rings of epithelial cells against a background of relatively less intense mesenchymal expression. Images are paired with identically processed controls in which the p66
Shc antibody was preabsorbed with the immunizing peptide. Silencing efficiency was confirmed by immunoblotting, in triplicate, lung explants transfected with either no siRNA, GAPDH siRNA, or p66
Shc siRNA. Cells were cultured for 2 days before lysis and Western analysis (E). Note the decreased expression of p66
Shc compared with the persistent p52 Shc expression in p66 Shc siRNA-treated cells.
into the epithelial cells of cultured embryonic day (E) 11 fetal lung mouse explants by intratracheal microinjection. We found that lung morphogenesis and epithelial maturation were significantly altered by p66 Shc silencing, consistent with its temporal-spatial regulation of lung development.
METHODS
siRNA constructs. An isoform-specific p66
Shc siRNA (5=-GAA UGA GUC UCU GUC AUC GUC-3= and 5=-CGA UGA CAG AGA CUC AUU CCG-3=) was designed against nucleotides 236 -256 of murine p66
Shc based on Kisielow et al. (10); its efficiency and specificity have been previously demonstrated (14) . The annealed constructs were suspended in Oligofectamine (Life Technologies, Grand Island, NY) per the manufacturer's instructions, and Fast Green dye was added for visibility. Nonsilencing siRNAs were purchased from Qiagen (Valencia, CA) and used as controls. To assess siRNA transfer, conjugates of nonsilencing siRNA and Cy5 fluorophore (Qiagen) were transfected.
Lung explants. Animals were maintained and used in accordance with a protocol approved by the Institutional Animal Care and Use Committee of the University of Southern California. Timed-pregnant female Swiss-Webster mice (Mus musculus) were killed at 11 days gestation by CO 2 asphyxiation that was continued for at least 1 min after apparent death. Dams were then subjected to cervical dislocation before necropsy and fetal lung isolation. To transfect epithelia with siRNA, lungs were cannulated with glass microinjection pipettes, and the bronchial trees were filled by microinjection; typically, 1 l of siRNA suspension was injected. Lung explants were cultured on polyvinylidene difluoride filters maintained at the air-liquid interface (EMD Millipore, Billerica, MA) of BGJb medium (Life Technologies) supplemented with 10 g/ml ascorbic acid. Medium was changed every 48 h. Cultures were maintained in 5% CO 2 at 37°C for up to 96 h.
Transfections and adenoviral infections of cultured cells. To obtain primary fetal lung type II cells, dams were killed on day 17 of gestation as described. The fetal lungs were isolated and dissociated with trypsin 0.1% in DMEM at 37°C for 20 min, and the fibroblasts and type II cells were isolated by differential adherence (13, 24) . Mv1Lu cells were purchased from ATCC (Manassas, VA). Cells were cultured in DMEM or MEM-␣ with 10% fetal calf serum and grown to 75% confluence in six-well plates before siRNA transfection and/or infection with adenoviruses encoding p66
Shc silently mutated to resist the siRNA (14) . To downregulate ShcA expression, cells cultured to 60% confluence in six-well plates were treated for 4 h with 3 l/well of 50 M siRNA suspended in 4 l Oligofectamine. Cells were rested for 48 h, starved overnight, and stimulated with 20 ng/ml EGF (R&D Systems, Minneapolis, MN). For adenoviral infections, transfected cells were rested for 24 h before overnight incubation with 5 ϫ 10 Western analysis. For immunoblotting, cells were dissociated in RIPA buffer [150 mM NaCl, 1% Nonidet P-40, 0.25% deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0, 2 mM EDTA, 1 mM NaVO 4, 10 mM NaF, and Complete Mini protease inhibitor mix (Roche, Indianapolis, IN)]. Homogenates were cleared by centrifugation at 14,000 g for 20 min, protein concentrations were determined by the bicinchoninic acid method (Thermo Pierce, Rockford, IL), and the protein contents were equalized. Samples were resolved by 10% SDS-PAGE and immunoblotted with a rabbit anti-Shc polyclonal antibody (BD Transduction Laboratories, San Jose, CA). Proteins were visualized by chemiluminescence (Pierce). Equal lane loading was confirmed by GAPDH immunoblotting of identical blots (i.e., equal volumes of the same samples), or by Coomassie blue staining of the transferred gel when GAPDH siRNA was used as an experimental control. Primary antibodies included rabbit anti-Shc (BD Transduction Laboratories), rabbit anti-PCNA (Zymed, South San Francisco, CA), rabbit anti-GAPDH (Cell Signaling Technologies, Beverly, MA), mouse anti-TTF-1 (Santa Cruz Biotechnology, Dallas, TX), rabbit anti-SP-B (EMD Millipore), rabbit anti pro-SP-C, and mouse anti-CC10 (both from Seven Hills Bioreagents, Cincinnati, OH).
Shc siRNA concentrations correlate with decreased cellular volumes and reduced branching. E11 lungs were isolated, the tracheae were cannulated, and the bronchial trees were filled with transfection mixtures (A) before culture for 3 days. Lungs were either not injected (B), injected with mixtures containing 1.6, 3.3, and 6.6 nM p66
Shc siRNA (C, D, and E, respectively), or injected with a suspension of 6.6 nM nonsilencing siRNA (F). Branching was assessed by counting terminal branches, and cross-sectional areas were quantified by point counting. Terminal branch counts decreased inversely with p66
Shc siRNA concentration (G), with lungs receiving 3.3 and 6.6 nM siRNA having significantly fewer terminal branches than control explants injected with nonsilencing siRNA (P ϭ 0.0033 and 0.0023, respectively). Branch counts correlated inversely with siRNA concentrations, suggesting a dose-dependent response. Lungs treated with 6.6 nM p66
Shc siRNA had significantly enlarged airway (P ϭ 0.001) and decreased epithelial (P ϭ 0.008) cross-sectional areas relative to explants treated with nonsilencing siRNA (H). Values represent means, and error bars represent SE. *P ϭ 0.0033 (G) and 0.001 (H). **P ϭ 0.0023 (G) and 0.008 (H). Immunohistochemistry. Specimens were fixed in 4% paraformaldehyde and embedded in paraffin. Before immunostaining, sections were deparaffinized in xylene and rehydrated in an ethanol gradient, and the antigens were retrieved in 0.01 M citrate buffer with 0.05% Tween 20, pH 6.0, for 30 min at 100°C. Sections were blocked in a casein-based reagent (Roche) and incubated successively with primary antibody and 1 g/ml goat anti-rabbit IgG antibody conjugated to Alexa 488 and/or 1 g/ml goat anti-mouse IgG antibody conjugated to Alexa 594 (both from Life Technologies) as appropriate. Primary antibodies included a rabbit antibody against amino acids 26 -42 of murine p66
Shc (16) , mouse anti-proliferating cell nuclear antigen (PCNA) (Zymed), monoclonal anti-smooth muscle actin (SMA) (Sigma, St. Louis, MO), rabbit anti-surfactant protein (SP)-A, rabbit anti-SP-B, rabbit anti-SP-C, mouse anti-thyroid transcription factor (TTF)-1, or mouse anti-Clara cell 10-kDa protein (CC10) (all from EMD Millipore). Cover slips were mounted with ProLong anti-fade reagent (Life Technologies), and antigens were visualized by epifluorescence microscopy.
Morphometry. The fraction of explant cross-sectional areas comprised of epithelium, mesenchyme, or incipient airspace was quantitated by point counting (1). Airway branching was estimated by terminal branch counts. PCNA-expressing cells were counted and normalized against the total number of epithelial cells within the same photographic field. Statistical comparisons were performed by Student's t-test assuming equal variance.
RT-PCR. Primary fetal lung type II cells were transfected with GAPDH or p66
Shc siRNA and/or infected with siRNA-resistant p66
Shc adenovirus as noted above, maintained in culture for 24 h, and then subjected to reverse transcription and real-time PCR for SP-B and SP-C mRNA as previously described (11) . Briefly, total RNA was isolated from embryonic lungs using a Qiagen RNeasy Micro Kit and reverse transcribed using SuperScript III (Life Technologies) per the manufacturer's directions. Real-time PCR quantitation of SP-B, SP-C, and ␤-actin cDNA was performed in a LightCycler with a Fast Start DNA SYBR Green Master Mix (Qiagen). The expression of target transcripts relative to that of cells treated with nonsilencing siRNA and infected with GFP virus was calculated with the ⌬⌬C t method (17) , where ␤-actin was used as the reference gene.
RESULTS
Nonsilencing siRNAs enter epithelial cells and have minimal effects on lung morphogenesis in vitro. The p66
Shc isoform is highly expressed in the epithelial cells of early embryonic lungs, where its function is largely uncharacterized. We postulated that its expression in this population could be reduced by injecting transfection suspensions containing isoform-specific siRNA in the tracheae of embryonic lungs. The explants could then be allowed to develop in vitro, and any resulting developmental perturbations could be attributed to p66
Shc silencing. To confirm that this method specifically transfects epithelial populations, Cy5 fluorochrome-conjugated nonsilencing siRNA was suspended in transfection reagent and microinjected in the tracheae of E11 lung explants until filled. Typically, 1 l of solution was used for each explant. After 3 days, lungs were visualized by epifluorescence microscopy. No fluorescence was apparent in untransfected lungs (Fig. 1A) . Intense fluorescence was observed only in the epithelial cells of microinjected lungs, demonstrating successful and selective transfection (Fig. 1B) . Because some spillover is inevitable, siRNA localization was also assessed in explants immersed in transfection mixtures containing fluorochrome-conjugated nonsilencing siRNA (Fig. 1C) . Overall uptake was weaker, and while some uptake was observed in nonepithelial populations, much of the fluorescence localized to epithelial populations. Brightfield micrographs of the same samples suggest that the development of these explants over 3 days in vitro was similar. Relative to uninjected lungs (Fig. 1D) , neither explants receiving intratracheal nonsilencing siRNA (Fig. 1E ) nor explants immersed in nonsilencing siRNA (Fig. 1F) exhibited altered growth or branching. These results suggested that epithelial cells could be transfected by tracheal siRNA injection, the specificity of this method is relatively robust, and that transfection alone did not appreciably alter lung morphogenesis in vitro.
Transfected siRNA decreases p66 Shc expression in cells and fetal lung explant cultures. The expression of p66
Shc was attenuated using an isoform-specific siRNA developed by Kisielow et al. (10) . We confirmed its silencing efficiency by tranfecting Swiss 3T3 cells with either nonsilencing or p66 Shc siRNA suspended in Oligofectamine per the manufacturer's directions. Cells were maintained in culture for 2 days before lysis. Western analysis of the lysates demonstrated efficient p66
Shc knockdown and very similar p52 Shc expression, confirming both isoform specificity and equal loading (Fig. 2E ).
Epithelial p66
Shc was then silenced in E11 lung explants by injecting the tracheae with transfection mixtures containing 6.6 nM of nonsilencing siRNA, GAPDH siRNA, or p66
Shc siRNA (Fig. 2, B, C, and D, respectively) . Lung explants were cultured for 3 days before fixation and immunostaining for p66
Shc using an isoform-specific antibody (16) . Sections immunostained with p66
Shc antibody preabsorbed overnight with a 10-fold concentration of the immunizing peptide demonstrating minimal nonspecific fluorescence. The expression of p66 Shc in explants transfected with nonsilencing siRNA or GAPDH siRNA was similar to that of noninjected media control explants, localizing to rings of epithelial cells against a background of relatively less intense mesenchymal expression. In contrast, epithelial p66
Shc expression in explants injected with p66
Shc siRNA was decreased to levels that were similar to that of the surrounding mesenchyme. Similarly transfected and cultured explants were lysed and immunoblotted, in triplicate, for Shc (Fig. 2E) . The expression of p66
Shc was reduced in explants injected with p66
Shc siRNA relative to otherwise identical explants treated with no siRNA or GAPDH siRNA. The expression of p52
Shc was unchanged, which also demon- Shc expression is decreased by p66 Shc siRNA. E: PCNA was highly expressed in 23% of the epithelial cells in uninjected explants, 23% in lungs injected with GAPDH siRNA, 21% in lungs injected with nonsilencing siRNA, and 34% in lungs treated with p66
Shc siRNA (*P ϭ 3 ϫ 10
Ϫ5
; **P ϭ 0.00017; ***P ϭ 0.00021). Values represent means and error bars represent SE. F: PCNA immunoblot of lung explants injected (in triplicate) with no siRNA, p66
Shc siRNA, or nonsilencing control siRNA as previously described. Lungs were cultured for 3 days before lysis and Western analysis. GAPDH immunoblot of the same samples confirms equal loading. Shc silencing attenuates epithelial maturation as assessed immunohistologically. The tracheae of E11 lung explants were injected with either 6.6 nM nonsilencing siRNA (A, C, and E) or p66
Shc siRNA (B, D, and F) and then cultured for 3 days. Airway differentiation was assessed by immunostaining for the proximal maturation markers Clara cell 10- 
kDa protein (CC10) (A and B) and thyroid transcription factor (TTF)-1 (C and D) and the alveolar markers surfactant protein (SP)-A (A and B), SP-B (C and D), and SP-C (E and F). Smooth muscle actin (SMA) was also assessed (C and D). Neither control nor experimental lungs expressed SP-A, suggesting that its expression was not induced by p66
Shc silencing. In contrast, the expression of TTF-1, CC10, SP-B, and SP-C was decreased by p66
Shc silencing. SMA expression was not overtly affected. Control images consist of merged red and green micrographs of identically processed and imaged sections to which no primary antibodies were applied. Shc siRNA in the epithelium of E11 lungs as previously described. Tracheae were injected with transfection mixtures containing 1.6, 3.3, and 6.6 nM p66
Shc siRNA (Fig. 3, C, D, and E, respectively) , maintained in culture for 3 days, and compared with identical control lungs that were either not injected or injected with 6.6 nM nonsilencing siRNA (Fig. 3, B and F, respectively) . Lung branching was quantitated by counting the terminal airspaces, and cellular cross-sectional areas were assessed by point counting (n Ն 5 in all cases). The results were compared by t-test assuming equal variance.
Terminal bud counts decreased inversely with p66
Shc siRNA concentration, with lungs receiving 3.3 and 6.6 nM siRNA having significantly fewer terminal buds than control explants injected with nonsilencing siRNA (P ϭ 0.0033 and 0.0023, respectively). Airways were significantly larger (P ϭ 0.001) and epithelial cross-sectional areas significantly decreased (P ϭ 0.008) in lung explants treated with 6.6 nM p66
Shc siRNA relative to control explants treated with nonsilencing siRNA. These findings indicate that epithelial p66
Shc expression contributes significantly to normal lung morphogenesis.
Epithelial p66
Shc siRNA increases PCNA expression. Because p66
Shc is a putative inhibitor of Ras activation, the lumenal enlargement associated with its silencing may result from increased epithelial proliferation. To assess this possibility, epithelial proliferation was assessed in lung explants transfected with 6.6 nM suspensions of either nonsilencing or p66
Shc siRNA. Sectioned explants were immunostained with antibodies against PCNA, a cofactor of DNA polymerase ␦ that accumulates in the nuclei during DNA synthesis and repair (18) , and cadherins, cell-surface proteins expressed by lung epithelial cells (7) . Epithelial nuclei were identified by DAPI counterstaining within cadherin-positive cells, and proliferation rates were estimated as proportions of nuclei that expressed PCNA. The efficacy of the p66
Shc silencing was evident from the enlarged airways and decreased epithelial p66 Shc expression. PCNA was expressed in 23% of the epithelial cells in uninjected explants (Fig. 4A) , 23% in explants transfected with GAPDH siRNA (Fig. 4B) , and 21% in lungs injected with nonsilencing siRNA (Fig. 4C) . In lungs treated with p66
Shc siRNA, 32% of the epithelial cells were PCNApositive (Fig. 4D) , a small but statistically significant difference (P ϭ 0.00021 relative to nonsilencing siRNA, P ϭ 0.00017 relative to GAPDH siRNA, and P ϭ 3 ϫ 10 Ϫ5 relative to uninjected media controls by t-test, n Ն 5 for all conditions; Fig. 4E ). Results from immunostaining were confirmed by immunoblotting (in triplicate) lysed whole lung explants injected with no siRNA, nonsilencing control siRNA, or p66 Shc siRNA before maintenance in culture for 4 days (Fig. 4F) . The increased cell proliferation associated with p66
Shc silencing is consistent with its putative function as a Ras antagonist and may account for the associated lumenal enlargement.
Shc siRNA was associated with decreased expression of SP-B, SP-C, TTF-1, and CC10. The proliferation of fetal cells often correlates inversely with their differentiation, leading us to speculate that p66
Shc silencing might also attenuate the maturation of cultured lung explants. Epithelial maturation was assessed by immunostaining for terminal airway differentiation markers. These markers included SP-A, -B, and -C, which are expressed in alveolar type II cells; CC10; and TTF-1, which is expressed in both bronchiolar and type II epithelial cells. The expression of SMA was also assessed. Explants injected with 6.6 nM siRNA suspension were compared with identical explants injected with nonsilencing control siRNA. Neither control (Fig. 5A) nor experimental (Fig. 5B) lungs expressed SP-A, indicating that SP-A expression was not induced by p66
Shc silencing. Conversely, SMA was expressed in lungs treated with either control or p66
Shc siRNA, with no apparent differences in quantity or localization. In contrast, the expression of CC10, TTF-1, SP-B, and SP-C was decreased in p66
Shc siRNA-treated lungs (Fig. 5 , B and D) relative to controls (Fig. 5, A and C) .
To confirm the immunohistological findings, cultured siRNA-injected lung explants were also subjected to Western analysis for distal and proximal epithelial maturational markers (Fig. 6A) . The expression of pro-SP-C was decreased by p66 Shc silencing relative to explants injected with either nonsilencing or GAPDH siRNAs. Similarly, CC10 expression was decreased by p66
Shc siRNA relative to nonsilencing control siRNA. Taken together, these results suggest that p66
Shc expression is necessary for the terminal differentiation of both distal and proximal pulmonary epithelial cells.
Silencing p66 Shc decreases the maturation of epithelial cells in vitro. Decreased epithelial maturation associated with transfection of p66
Shc siRNA in epithelial cells suggests that p66
Shc may directly regulate epithelial maturation, independent of Shc silencing attenuates epithelial maturation as assessed by immunoblotting. Lung explants were microinjected with 6.6 nM nonsilencing, p66 Shc , or GAPDH siRNA, cultured for 3 days, and lysed for Western analysis. The expression of CC10 (A, left) and SP-C (A, right) was reduced by p66
Shc silencing relative to nonsilencing or GAPDH controls. Coomassie blue staining of the transferred gel (left) and GAPDH immunoblotting of the same samples (right) confirm equivalent loading. Maturation was also evaluated in primary type II cells transfected with either nonsilencing control siRNA or p66
Shc siRNA. Immunoblots of cells cultured for 2 days after transfection showed decreased SP-B and decreased p66
Shc expression (B, left); divided panels were scanned from the same membrane. TTF-1 expression was similarly reduced (B, right). GAPDH immunoblot of the same samples confirms equal loading. To assess SP-B and SP-C transcription, similarly transfected type II cells were cultured 24 h before RT-PCR. Indicated cells were maintained in 20 ng/ml epidermal growth factor (EGF). p66
Shc silencing significantly reduced SP-B transcription in the presence of EGF (C, left, P ϭ 0.0234) and SP-C mRNA in the absence of EGF (C, right, P ϭ 0.048, n ϭ 3 for all). SP-B and SP-C transcription was increased by viral p66
Shc expression, but differences were not significant. Maturational markers were also assessed in Mv1Lu cells transfected with either nonsilencing (Ctl) or p66
Shc siRNA. TTF-1 (D, top) and, to a lesser extent, SP-C expression was reduced by p66
Shc silencing (D, second). Equal volumes of the same samples were loaded on each gel. Efficient p66 Shc silencing and equal loading were confirmed by Shc reprobe of the SP-C membrane (D, third) and GAPDH reprobe of the TTF-1 membrane (D, bottom) . The proliferative effects of p66
Shc silencing were also assessed in Mv1Lu cells. Mv1Lu cells were transfected with nonsilencing (Ctl) and p66
Shc siRNA as above. Cells were maintained for 24 h before immunoblotting equal volumes of the same samples for PCNA (E, top), p66
Shc (E, middle), and GAPDH (E, bottom).
paracrine or cell-cell interactions within the developing lung. To assess this possibility, type II cells were isolated from the lungs of fetal mice at 17 days gestation (11), rested overnight, and transfected with either p66 Shc or nonsilencing control siRNA. Transfected cells were cultured for 48 h. Immunoblotting confirmed the efficacy of p66
Shc knockdown and demonstrated reduced SP-B expression relative to identical cells transfected with nonsilencing control siRNA (Fig. 6B, left) . Similarly, TTF-1 was decreased by p66
Shc knockdown (Fig.  6B, right) .
Transcription of SP-B and SP-C mRNA in these cells was also evaluated by RT-PCR (Fig. 6C) . Type II cells were isolated, rested overnight, and transfected with either p66
Shc or nonsilencing control siRNA while being infected with adenoviral constructs expressing either GFP or p66
Shc silently mutated to resist siRNA degradation (14) . After 24 h in culture, cells were lysed for RT-PCR. Because the Shc isoforms are activated by EGF, selected cells were also exposed to 20 ng/ml EGF, which increased SP-C but not SP-B transcription (P ϭ 0.0017, n ϭ 3). Transfection with p66
Shc siRNA decreased the transcription of both SP-B and SP-C. For SP-B, this decrease was significant in the presence but not the absence of EGF (P ϭ 0.0234, n ϭ 3). For SP-C, the decrease was significant in the absence of EGF (P ϭ 0.048, n ϭ 3) and trended toward significance in the presence of EGF (P ϭ 0.078, n ϭ 3). SP-B and SP-C transcripts were increased by the p66 Shc virus, but the differences did not achieve significance.
The effects of p66 Shc silencing were also assessed on Mv1Lu mink lung epithelial cells, which secrete surfactant (12) . TTF-1 and, to a lesser extent, SP-C protein expression were reduced by p66
Shc siRNA relative to identical cells transfected with nonsilencing control siRNA (Fig. 6D) . These results indicate that p66
Shc directly regulates the maturation of immortalized and primary fetal lung epithelial cells.
DISCUSSION
The expression of p66
ShcA varies dramatically during lung development and injury response. Pulmonary p66 Shc protein content decreases by 90% during the last day of murine development, by 80% between 125 and 175 days of baboon gestation, and by 87% between 18 and 24 wk of human pregnancy (15, 16) . These periods correspond to the early saccular stage of mouse lung development (30) , the saccular stage of baboon lung development (2) , and the late canalicular stage of human lung development (3) . Differences in the timing of p66
Shc attenuation reflect variations in ontogeny among these species and suggest that p66
Shc regulates aspects of lung development that occur before alveolarization and are conserved across mammalian orders.
These results provide some insight to the morphological regulation conferred by p66
Shc . Epithelial p66 Shc silencing is associated with enlarged incipient airspaces and increased epithelial proliferation. The p66
Shc isoform is especially abundant in rapidly proliferating cells during development, injury recovery, and neoplasia (15, 16, 28) . Because many of the growth factors that induce cell proliferation are mediated by Ras and Erk MAP kinases, p66
Shc may be expressed as inhibitory feedback on Ras activation. Removing the inhibitory limb of that feedback loop would increase epithelial proliferation, expand the saccular perimeters, and, hence, the volumes of incipient airspaces.
In developing mouse lungs, SP-B and SP-C are histologically detectable at day 11 and CC10 at day 17 (32) . Murine p66
Shc is downregulated on the last day of gestation, after the induction of these terminal differentiation markers. Human p66
Shc is downregulated between 18 and 24 wk gestation (15), after the appearance of CC10 in the trachea at 15 wk and the bronchi at 14 wk (8) . The drop in human p66
Shc expression occurs before the expression of active SP-C at 25 wk gestation but after the induction of SP-C precursors (9) . It is tempting to speculate that p66
Shc silencing delays the developmental expression of these proteins. However, explants TTF-1 expression is also attenuated by p66
Shc , and this marker is present from the onset of mouse lung morphogenesis at day 10 (32). Moreover, p66
Shc silencing decreases the expression of TTF-1 in type II cells isolated from E17 mice. These findings suggest that p66
Shc is necessary to maintain the differentiated phenotype. Because p66
Shc essentially disappears from the mouse lung at E18, this necessity appears to be temporary.
The attenuated epithelial maturation noted in the current study is less compatible with the known functions of p66 Shc . While broadly consistent with the principle that proliferation antagonizes the differentiation of fetal cells, we are unaware of any mechanism by which p66
Shc directly induces the differentiation of any cell type. Besides Ras antagonism, p66
Shc is characterized as an oxidative stress mediator (19) intimately involved in mitochondrial apoptosis (6, 23) and aging (21, 27) . Moreover, embryonic p66
Shc expression is associated with the developmental arrest of bovine embryos (4, 5) . We speculate that p66
Shc may mediate additional as yet uncharacterized signaling functions that regulate the differentiation of fetal lung epithelial cells.
